| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS)
|
Lewin, Jeremy
|
|
|
144 |
C |
p. 360-367
|
artikel
|
| 2 |
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial
|
R. Ferreira, Arlindo
|
|
|
144 |
C |
p. 351-359
|
artikel
|
| 3 |
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy
|
Sena, Laura A.
|
|
|
144 |
C |
p. 302-309
|
artikel
|
| 4 |
Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer
|
Battisti, Nicolò Matteo Luca
|
|
|
144 |
C |
p. 269-280
|
artikel
|
| 5 |
Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments
|
Anderson, Richard A.
|
|
|
144 |
C |
p. 310-316
|
artikel
|
| 6 |
Can we recommend surgical treatment to the octogenarian with periampullary cancer?: National database analysis in South Korea
|
Kang, Chang M.
|
|
|
144 |
C |
p. 81-90
|
artikel
|
| 7 |
Cardiac magnetic resonance imaging of transient myocardial dysfunction in a patient treated with checkpoint-targeted immunotherapy
|
Camastra, Giovanni
|
|
|
144 |
C |
p. 389-391
|
artikel
|
| 8 |
Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience
|
Berlanga, P.
|
|
|
144 |
C |
p. 1-8
|
artikel
|
| 9 |
Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis
|
Jones, Robert P.
|
|
|
144 |
C |
p. 368-381
|
artikel
|
| 10 |
Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al
|
De Vincentis, Giuseppe
|
|
|
144 |
C |
p. 392-394
|
artikel
|
| 11 |
Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis
|
Park, Sejung
|
|
|
144 |
C |
p. 49-60
|
artikel
|
| 12 |
Corrigendum to “A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation” [Eur J Canc 131 (2020) 68–75]
|
Lala, Mallika
|
|
|
144 |
C |
p. 400
|
artikel
|
| 13 |
Corrigendum to “Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group” [European Journal of Cancer. Volume 140, November 2020, Pages 1-10]
|
Ditto, Antonino
|
|
|
144 |
C |
p. 399
|
artikel
|
| 14 |
Corrigendum to “Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)” [Eur J Canc. vol. 139 November (2020) Pages 149–168]
|
Ferrandina, Gabriella
|
|
|
144 |
C |
p. 397-398
|
artikel
|
| 15 |
Exosomes and exosomal RNAs in breast cancer: A status update
|
Lakshmi, Sreerenjini
|
|
|
144 |
C |
p. 252-268
|
artikel
|
| 16 |
Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: An unexpected case of fludarabine-associated progressive leukoencephalopathy
|
Winter, Sebastian F.
|
|
|
144 |
C |
p. 178-181
|
artikel
|
| 17 |
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients
|
Cantini, Luca
|
|
|
144 |
C |
p. 41-48
|
artikel
|
| 18 |
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer
|
Manca, Paolo
|
|
|
144 |
C |
p. 31-40
|
artikel
|
| 19 |
Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck
|
Amit, Moran
|
|
|
144 |
C |
p. 169-177
|
artikel
|
| 20 |
Kinomic profiling of tumour xenografts derived from patients with non–small cell lung cancer confirms their fidelity and reveals potentially actionable pathways
|
Tabbò, Fabrizio
|
|
|
144 |
C |
p. 17-30
|
artikel
|
| 21 |
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study
|
Jeong, Jae Ho
|
|
|
144 |
C |
p. 341-350
|
artikel
|
| 22 |
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
|
Robert, Caroline
|
|
|
144 |
C |
p. 182-191
|
artikel
|
| 23 |
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients
|
Ribelles, Nuria
|
|
|
144 |
C |
p. 224-231
|
artikel
|
| 24 |
Nivolumab activity in advanced refractory malignant peritoneal mesothelioma
|
Becker, Ondine
|
|
|
144 |
C |
p. 386-388
|
artikel
|
| 25 |
Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer
|
Kasper, Stefan
|
|
|
144 |
C |
p. 291-301
|
artikel
|
| 26 |
Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials
|
Caramanna, Ivan
|
|
|
144 |
C |
p. 162-168
|
artikel
|
| 27 |
Outcomes of local thoracic surgery in patients with stage IV non–small-cell lung cancer: A SEER-based analysis
|
Jia, Jianlong
|
|
|
144 |
C |
p. 326-340
|
artikel
|
| 28 |
PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade
|
Yoshida, Hironori
|
|
|
144 |
C |
p. 317-325
|
artikel
|
| 29 |
Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era
|
Rodriguez-Freixinos, Víctor
|
|
|
144 |
C |
p. 200-214
|
artikel
|
| 30 |
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)
|
Li, Chengqiang
|
|
|
144 |
C |
p. 232-241
|
artikel
|
| 31 |
Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer
|
Rasmussen, Louise S.
|
|
|
144 |
C |
p. 72-80
|
artikel
|
| 32 |
Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials
|
Sinicrope, Frank A.
|
|
|
144 |
C |
p. 101-112
|
artikel
|
| 33 |
Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
|
Colle, Raphael
|
|
|
144 |
C |
p. 9-16
|
artikel
|
| 34 |
Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial
|
Kosmala, Rebekka
|
|
|
144 |
C |
p. 281-290
|
artikel
|
| 35 |
Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer
|
den Uil, Sjoerd H.
|
|
|
144 |
C |
p. 91-100
|
artikel
|
| 36 |
Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)
|
Nakayama, Goro
|
|
|
144 |
C |
p. 61-71
|
artikel
|
| 37 |
Response to comment on “Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer”
|
van der Doelen, Maarten J.
|
|
|
144 |
C |
p. 395-396
|
artikel
|
| 38 |
SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry
|
Moritz, Rose K.C.
|
|
|
144 |
C |
p. 382-385
|
artikel
|
| 39 |
Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer
|
Boers, Jorianne
|
|
|
144 |
C |
p. 151-161
|
artikel
|
| 40 |
Skin lesions of face and scalp – Classification by a market-approved convolutional neural network in comparison with 64 dermatologists
|
Haenssle, Holger Andreas
|
|
|
144 |
C |
p. 192-199
|
artikel
|
| 41 |
Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry
|
van Zeijl, M.C.T.
|
|
|
144 |
C |
p. 242-251
|
artikel
|
| 42 |
The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma
|
Dimitriou, Florentia
|
|
|
144 |
C |
p. 215-223
|
artikel
|
| 43 |
The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology
|
Wienke, Judith
|
|
|
144 |
C |
p. 123-150
|
artikel
|
| 44 |
Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials – A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting
|
Brok, Jesper
|
|
|
144 |
C |
p. 113-122
|
artikel
|
Tijdschrift beschrijving